Trial Profile
A multicentre, multinational, randomised, open study to establish the optimal method for initiating and maintaining Lantus [Rm] (insulin glargine) therapy based on a comparison of two treatment algorithms to determine optimal metabolic outcomes, safety, and satisfaction in subjects with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2009
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms AT.LANTAS
- Sponsors Sanofi
- 28 Nov 2006 New trial record.